Acorda Parkinson's drug results shot its stock up 13%. Why Wall Street is still cautious

Acorda Parkinson's drug results shot its stock up 13%. Why Wall Street is still cautious


Acorda Therapeutics Inc. shares shot up 13.5% in heavy volume Thursday after the company said its Parkinson's drug had positive results in a late-stage clinical trial. latest release: patients who took its drug, called inhaled L-Dopa and intended for "off" times when patients aren't responding well to medication, showed a statistically significant improvement in motor function, and there were no indications of safety concerns.



from Biotech News